Dr. Hoos on Why Melanoma is Amenable to Immunotherapy

Axel Hoos, MD, PhD
Published: Tuesday, Jul 26, 2011



Axel Hoos, MD, PhD, the medical lead in Immunology/Oncology at Bristol-Myers Squibb, describes that melanoma has often been viewed as a disease that is susceptible to immunotherapy simply because of the various antigens that present in the disease. Hoos goes on to explain that other indications will need to be examined more in depth and could result in another disease that is just as amendable to immunotherapy as melanoma.
SELECTED
LANGUAGE


Axel Hoos, MD, PhD, the medical lead in Immunology/Oncology at Bristol-Myers Squibb, describes that melanoma has often been viewed as a disease that is susceptible to immunotherapy simply because of the various antigens that present in the disease. Hoos goes on to explain that other indications will need to be examined more in depth and could result in another disease that is just as amendable to immunotherapy as melanoma.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Publication Bottom Border
Border Publication
x